.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EA04_Bosutinib.Bosutinib

Information

Bosutinib is an oral tyrosine kinase inhibitor used primarily for the treatment of chronic myelogenous leukemia (CML) in adults. It is approved and utilized as a targeted therapy in patients who are resistant or intolerant to prior therapy.

Pharmacokinetics

Pharmacokinetic parameters are reported for adult patients with chronic phase chronic myelogenous leukemia after oral administration of bosutinib.

References

1. Abbas, R, & Hsyu, PH (2016). Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib. Clinical pharmacokinetics 55(10) 1191–1204. DOI:10.1007/s40262-016-0391-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27113346

2. Hsyu, PH, et al., & Amantea, M (2014). Population pharmacokinetic and pharmacodynamic analysis of bosutinib. Drug metabolism and pharmacokinetics 29(6) 441–448. DOI:10.2133/dmpk.DMPK-13-RG-126 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24919837

3. Abbas, R, et al., & Sonnichsen, D (2012). Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. Clinical therapeutics 34(9) 2011–9.e1. DOI:10.1016/j.clinthera.2012.07.006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22884766

Revisions

• 06/2025 initial generated model